Esophageal adenocarcinoma

Reflux-promoting drugs may raise risk for esophageal adenocarcinoma.

August 3, 2000

NEW YORK, August 2 (Praxis Press) An increase in the incidence of esophageal adenocarcinoma was first reported in the 1970s, a time period during which drugs that relax the lower esophageal sphincter (LES) had gained widespread use. Lagergren and colleagues studied the association of upper gastrointestinal tract cancers and use of several classes of LES-relaxing drugs. The study included 189 subjects with esophageal adenocarcinoma, 262 with adenocarcinoma of the gastric cardia, 167 with esophageal squamous cell carcinoma, and 820 control subjects. When compared with patients who had never used LES-relaxing drugs, patients who used them daily for more than five years had an estimated incidence rate ratio of 3.8 for esophageal adenocarcinoma; this association was strongest for anticholinergic drugs. In contrast, no association was noted for adenocarcinoma of the gastric cardia or esophageal squamous cell carcinoma. The therapeutic benefits of LES-relaxing drugs may be slightly offset by an increased risk of esophageal adenocarcinoma.

Popular Now

  1. Consilience, Episode 3: Cancer, Obscured
  2. RNAi’s Future in Drug-Target Screening
    News Analysis RNAi’s Future in Drug-Target Screening

    A recent CRISPR study contradicted years of RNA interference research on a well-studied cancer drug target. But is it the last nail in the coffin for RNAi as a screening tool? 

  3. A History of Screening for Natural Products to Fight Cancer
  4. Streakers, Poopers, and Performers: The Wilder Side of Wildlife Cameras
AAAS